We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Systematic Review And Meta-Analysis Of Psoriasis Treatments.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01425138
First Posted: August 29, 2011
Last Update Posted: September 29, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of Connecticut School of Pharmacy and Hartford Hospital
Information provided by (Responsible Party):
Pfizer
  Purpose
This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data.

Condition
Psoriasis

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Biologic And Non-biologic Systemic Treatments For Moderate To Severe Plaque Psoriasis: A Systematic Review & Meta-Analysis

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Physician Global Assessment (PGA)
  • Dermatology Life Quality Index (DLQI)
  • Short-Form 36 (SF-36)

Secondary Outcome Measures:
  • No secondary outcomes [ Time Frame: No secondary outcomes ]

Estimated Enrollment: 0
Study Start Date: June 2009
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Psoriasis
Published data on moderate-to-severe plaque psoriasis.

Detailed Description:
This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data. We included all published randomized controlled trials of treatments for moderate-to-severe psoriasis that met the study inclusion criteria.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Moderate-to-severe plaque psoriasis published trials.
Criteria

Inclusion Criteria:

  • Randomized controlled clinical trials of treatments for moderate-to-severe plaque psoriasis.
  • Trials had to evaluate at least one of the following: Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and/or the Short-Form 36 (SF-36).

Exclusion Criteria:

Observational studies

  • Trials that did not report the Physician's Global Assessment (PGA),
  • Dermatology Life Quality Index (DLQI) or the Short-Form 36 (SF-36).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01425138


Sponsors and Collaborators
Pfizer
University of Connecticut School of Pharmacy and Hartford Hospital
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01425138     History of Changes
Other Study ID Numbers: A3921142
First Submitted: August 26, 2011
First Posted: August 29, 2011
Last Update Posted: September 29, 2011
Last Verified: September 2011

Keywords provided by Pfizer:
psoriasis
systematic review
meta-analyses

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases